Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;50(2-3):276-85.
doi: 10.1007/s12026-011-8213-2.

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents

Hiam Naiditch  1 , Michael R Shurin, Galina V Shurin
Affiliations

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents

Hiam Naiditch et al. Immunol Res. 2011 Aug.

Abstract

Recent findings in humans and numerous experimental models provide evidence of the important role of immune regulatory cells in cancer and various diseases. "Myeloid regulatory cells" (MRC) include myeloid-derived suppressor cells, regulatory dendritic cells, regulatory macrophages, and subsets of granulocytes that expand during pathologic conditions and that have the ability to suppress cellular immunity. A decrease in MRC population and/or activity has been shown to have positive immune-potentiating effects. Several clinical trials have thus been initiated with the goal of manipulating the expansion or activation of these cells and thereby improving patient immune responses. New data from our own and other laboratories recently revealed that ultralow noncytotoxic doses of certain chemotherapeutic drugs could up-regulate antitumor immunity by modulating the formation, differentiation, and/or function of MRC. This new phenomenon, termed "chemomodulation," allows for the regulation of the tumor microenvironment without the undesirable toxic effects associated with conventional chemotherapy. However, further studies are required before this new targeted therapy can find its way to patients with cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Med. 2007 Jan;13(1):54-61 - PubMed
    1. J Immunol. 2010 Jul 1;185(1):203-10 - PubMed
    1. Eur J Immunol. 2010 Jan;40(1):22-35 - PubMed
    1. J Immunol. 2001 May 1;166(9):5398-406 - PubMed
    1. J Immunother. 2010 Feb-Mar;33(2):211-8 - PubMed

MeSH terms

Substances

LinkOut - more resources